Tertiary lymphoid tissues: a regional hub for kidney inflammation.

aging chronic inflammation chronic kidney disease fibroblast tertiary lymphoid tissue

Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402

Informations de publication

Date de publication:
23 Jan 2023
Historique:
received: 19 01 2021
pubmed: 11 7 2021
medline: 26 1 2023
entrez: 10 7 2021
Statut: ppublish

Résumé

Tertiary lymphoid tissues (TLTs) are inducible ectopic lymphoid tissues that develop at sites of chronic inflammation in nonlymphoid organs. As with lymph nodes, TLTs initiate adaptive immune responses and coordinate local tissue immunity. Although virtually ignored for decades, TLTs have recently received a great deal of attention for their ability to influence disease severity, prognosis and response to therapy in various diseases, including cancer, autoimmune disorders and infections. TLTs are also induced in kidneys of patients with chronic kidney diseases such as immunoglobulin A nephropathy and lupus nephritis. Nevertheless, TLTs in the kidney have not been extensively investigated and their mechanism of development, functions and clinical relevance remain unknown, mainly because of the absence of adequate murine kidney TLT models and limited availability of human kidney samples containing TLTs. We recently found that aged kidneys, but not young kidneys, exhibit multiple TLTs after injury. Interestingly, although they are a minor component of TLTs, resident fibroblasts in the kidneys diversify into several distinct phenotypes that play crucial roles in TLT formation. Furthermore, the potential of TLTs as a novel kidney injury/inflammation marker as well as a novel therapeutic target for kidney diseases is also suggested. In this review article we describe the current understanding of TLTs with a focus on age-dependent TLTs in the kidney and discuss their potential as a novel therapeutic target and kidney inflammation marker.

Identifiants

pubmed: 34245300
pii: 6318782
doi: 10.1093/ndt/gfab212
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

26-33

Subventions

Organisme : Japan Agency for Medical Research and Development
ID : grants AMED-CREST20gm1210009, 20gm5010002, JP20gm0610011 and JP20lm0203006
Organisme : KAKENHI Grant-in-Aids for Scientific Research B
ID : 20H03697
Organisme : Japan Society for the Promotion of Science
Organisme : World Premier International Research Center Initiative and the Ministry of Education, Culture, Sports, Science and Technology

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Auteurs

Yuki Sato (Y)

Medical Innovation Center, TMK Project, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Masaru Tamura (M)

Technology and Development Team for Mouse Phenotype Analysis, Japan Mouse Clinic, RIKEN BioResource Research Center (BRC), Tsukuba, Japan.

Motoko Yanagita (M)

Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH